8-K: Phathom Pharmaceuticals Reports Q4 and Full Year 2023 Results, Highlights Strong VOQUEZNA Launch

Phathom Pharmaceuticals launched VOQUEZNA for Erosive GERD in November 2023, achieving $0.7 million in net revenue for the fourth quarter and securing expanded commercial coverage.

Summary

• Phathom Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, highlighting the commercial launch of VOQUEZNA for Erosive GERD.
• The company achieved net revenues of $0.7 million in Q4 2023 from VOQUEZNA sales.
• Over 14,000 prescriptions for VOQUEZNA products have been written since launch, with over 3,800 filled by February 23, 2024.
• Phathom secured expanded commercial coverage for VOQUEZNA, reaching approximately 60 million covered lives, representing 38% of total U.S. commercial lives.
• The company's term loan facility was expanded to $300 million, with up to an additional $160 million available, extending the cash runway through 2026.
• Research and development expenses decreased to $49.9 million for the full year 2023, down from $71.4 million in 2022.
• General and administrative expenses increased to $117.9 million for the full year 2023, up from $101.0 million in 2022, primarily due to stock-based compensation and commercial infrastructure buildout.
• The net loss for the full year 2023 was $201.6 million, compared to $197.7 million in 2022.
• Non-GAAP adjusted net loss for the full year 2023 was $129.7 million, compared to $157.4 million in 2022.
• As of December 31, 2023, cash and cash equivalents were $381.4 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with the successful launch of VOQUEZNA and expanded loan facility, but the significant net loss and reliance on external funding temper the overall sentiment.

Positives

• The successful launch of VOQUEZNA in November 2023 marks a significant milestone for the company.
• Strong early demand for VOQUEZNA is indicated by the number of prescriptions written and filled.
• Expanded commercial coverage provides access to a large portion of the U.S. market.
• The expanded loan facility strengthens the company's financial position and extends its cash runway.
• The decrease in R&D expenses demonstrates improved cost management.
• The FDA acceptance of the NDA for Non-Erosive GERD is a positive step towards expanding VOQUEZNA's market potential.
• The company is actively pursuing additional indications for VOQUEZNA, including As Needed dosing and treatment for EoE.

Negatives

• The company reported a net loss of $201.6 million for the full year 2023.
• General and administrative expenses increased significantly due to stock-based compensation and commercial infrastructure buildout.
• The company is still reliant on external funding, with a significant portion of its cash runway dependent on the expanded loan facility.

Risks

• The commercial success of VOQUEZNA depends on market acceptance, coverage, and reimbursement levels.
• The company may need to raise additional capital sooner than expected if product revenues are lower than anticipated or expenses are higher.
• Clinical development of vonoprazan carries inherent risks, including potential adverse side effects or inadequate efficacy.
• The company relies on third parties for manufacturing, research, and testing.
• Regulatory approvals and timelines are subject to uncertainty.
• The company's ability to access additional capital under its term loan facility is subject to certain conditions.
• The company's intellectual property protection and non-patent regulatory exclusivity for vonoprazan are subject to risks.
• The company must comply with its license agreement with Takeda.

Future Outlook

Phathom expects to launch VOQUEZNA for Non-Erosive GERD upon FDA approval, anticipated in Q3 2024, and is planning Phase 3 and Phase 2 trials for additional indications. The company believes it has sufficient capital to fund operations through the end of 2026.

Management Comments

• Terrie Curran, President and CEO of Phathom, stated that 2023 was transformative for the company, culminating with the launch of VOQUEZNA.
• Management is pleased with the early launch progress, including physician and payer reception to VOQUEZNA.
• The company anticipates prescription volume to grow as formulary coverage continues to build.
• Management expects the potential approval of VOQUEZNA for Non-Erosive GERD to unlock the largest segment of the GERD market.

Industry Context

The launch of VOQUEZNA represents the first new class of treatment for Erosive GERD approved in the U.S. in over three decades, positioning Phathom as a key player in the gastrointestinal therapeutics market. The company is also targeting the Non-Erosive GERD market, which is a substantial segment of the U.S. GERD population.

Comparison to Industry Standards

• Phathom's launch of VOQUEZNA is a significant event in the GERD treatment landscape, which has been dominated by proton pump inhibitors (PPIs) for many years.
• The company's focus on a potassium-competitive acid blocker (PCAB) represents a novel approach compared to traditional PPIs.
• The reported 14,000 prescriptions written since launch is a positive early indicator, but it is still early to compare to established competitors.
• The company's ability to secure coverage for 60 million lives is a strong start, but it will need to continue to expand coverage to compete effectively.
• Companies like Takeda (who Phathom has a license agreement with) and other major pharmaceutical companies with established GERD treatments will be key competitors.
• The company's R&D spend is lower than some of its larger competitors, but this is expected given its stage of development.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the company's future prospects.
• Employees will be affected by the company's growth and commercial success.
• Customers (patients) will benefit from the availability of new treatment options for GERD and H. pylori infection.
• Suppliers and creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Phathom will continue to expand commercial coverage for VOQUEZNA.
• The company anticipates FDA approval for VOQUEZNA for Non-Erosive GERD in Q3 2024.
• Phathom will initiate a Phase 3 trial for As Needed dosing of VOQUEZNA for Non-Erosive GERD.
• The company will commence a Phase 2 study for VOQUEZNA as a potential treatment for Eosinophilic Esophagitis (EoE).

Key Dates

Keywords

VOQUEZNA, vonoprazan, Erosive GERD, Non-Erosive GERD, H. pylori, gastrointestinal, pharmaceuticals, FDA, PBM, clinical trials, commercial launch, financial results